Search Results
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
School of Nursing and Midwifery, Institute of Clinical Sciences, University of Birmingham, UK
Search for other papers by Sherwin Criseno in
Google Scholar
PubMed
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Search for other papers by Helena Gleeson in
Google Scholar
PubMed
Search for other papers by Andrew A Toogood in
Google Scholar
PubMed
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Search for other papers by Neil Gittoes in
Google Scholar
PubMed
Search for other papers by Anne Topping in
Google Scholar
PubMed
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK
Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Search for other papers by Niki Karavitaki in
Google Scholar
PubMed
2006 155 61 – 71 . ( https://doi.org/10.1530/eje.1.02191 ) 3 Johannsson G & Ragnarsson O . Growth hormone deficiency in adults with hypopituitarism are – what are the risks and can they be eliminated by therapy? Journal of Internal Medicine
Search for other papers by Izabelle Lövgren in
Google Scholar
PubMed
Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK
Search for other papers by Azadeh Abravan in
Google Scholar
PubMed
Search for other papers by Abigail Bryce-Atkinson in
Google Scholar
PubMed
Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK
Search for other papers by Marcel van Herk in
Google Scholar
PubMed
-term quality of life for the patients but also benefit the healthcare system financially by reducing the overall treatment costs, as life-long hormone replacement therapy may be avoided. This review aims to address the late effects of cranial RT on the
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Ken K Y Ho in
Google Scholar
PubMed
Search for other papers by Bradley S Miller in
Google Scholar
PubMed
Search for other papers by Ignacio Bergada in
Google Scholar
PubMed
Search for other papers by Alan D Rogol in
Google Scholar
PubMed
hormone deficiencies, low serum IGF1 levels (specifically IGF1 SDS <−2), and a history of sellar mass lesion, pituitary surgery, or radiation therapy are likely (>95%) to have GHD and these patients can forego GH stimulation testing ( 4 , 5 ). In general
Search for other papers by Dan Liang in
Google Scholar
PubMed
Search for other papers by Han Chen in
Google Scholar
PubMed
Search for other papers by Li-Yong Zhong in
Google Scholar
PubMed
-term neuroendocrine outcomes, the multidisciplinary therapy team should consider constant exogenous hormone replacement treatment for sellar-predominant lesions, and reduced hormone replacement dose for non-sellar-predominant patients. To explore therapeutic influence
Search for other papers by Brijesh Krishnappa in
Google Scholar
PubMed
Search for other papers by Ravikumar Shah in
Google Scholar
PubMed
Search for other papers by Saba Samad Memon in
Google Scholar
PubMed
Search for other papers by Chakra Diwaker in
Google Scholar
PubMed
Search for other papers by Anurag R Lila in
Google Scholar
PubMed
Search for other papers by Virendra A Patil in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Search for other papers by Tushar R Bandgar in
Google Scholar
PubMed
observed, reserving supraphysiological dose of glucocorticoid therapy for those with severe or progressive neurologic deficits. Anterior pituitary hormonal (APH) recovery rate was highest with glucocorticoids (45.5%) when compared to surgery (14%) and
Princess Máxima Center for Pediatric Oncology, AB Utrecht, The Netherlands
Search for other papers by Ichelle Maa van Roessel in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, AB Utrecht, The Netherlands
Search for other papers by Boudewijn Bakker in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, AB Utrecht, The Netherlands
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
Search for other papers by Wassim Chemaitilly in
Google Scholar
PubMed
to the regional or national bodies that have formulated them ( 2 , 3 , 4 ). For these reasons, gaps in knowledge of the true risk conferred by hormone replacement therapy in CCS continue to represent a challenge, as best illustrated by the
Search for other papers by David S McLaren in
Google Scholar
PubMed
Search for other papers by Aarani Devi in
Google Scholar
PubMed
Search for other papers by Nikolaos Kyriakakis in
Google Scholar
PubMed
Search for other papers by Michelle Kwok-Williams in
Google Scholar
PubMed
Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Robert D Murray in
Google Scholar
PubMed
the use of proton therapy for the treatment of medulloblastoma has reduced the incidence of primary hypothyroidism, sex hormone deficiency, and the need for any hormone replacement therapy ( 51 , 52 ). One study reported that those treated with
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Mette Marie Baunsgaard in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Anne Sophie Lind Helligsoe in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Louise Tram Henriksen in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Torben Stamm Mikkelsen in
Google Scholar
PubMed
Search for other papers by Michael Callesen in
Google Scholar
PubMed
Search for other papers by Britta Weber in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Henrik Hasle in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Niels Birkebæk in
Google Scholar
PubMed
, endocrine data including growth data and hormone replacement therapy were retrieved from the charts. When calculating the cumulative CNS irradiation doses, both whole brain irradiation and boost irradiation were included, and the median cumulative CNS
Search for other papers by Vanderlan O Batista in
Google Scholar
PubMed
Search for other papers by Michael Kellner in
Google Scholar
PubMed
Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Search for other papers by Walter Lisboa in
Google Scholar
PubMed
Search for other papers by André Faro in
Google Scholar
PubMed
Search for other papers by Lucas B Santos in
Google Scholar
PubMed
Search for other papers by Enaldo V Melo in
Google Scholar
PubMed
Search for other papers by Alécia A Oliveira-Santos in
Google Scholar
PubMed
Search for other papers by Carla R P Oliveira in
Google Scholar
PubMed
Search for other papers by Viviane C Campos in
Google Scholar
PubMed
Search for other papers by Cynthia S Barros-Oliveira in
Google Scholar
PubMed
Search for other papers by Elenilde G Santos in
Google Scholar
PubMed
Search for other papers by Nathalie O Santana in
Google Scholar
PubMed
Search for other papers by Keila R Villar-Gouy in
Google Scholar
PubMed
Search for other papers by Ângela C Leal in
Google Scholar
PubMed
Search for other papers by Rivia S Amorim in
Google Scholar
PubMed
Search for other papers by Davi A Oliveira Simões in
Google Scholar
PubMed
Search for other papers by Manuel H Aguiar-Oliveira in
Google Scholar
PubMed
deficits of other pituitary hormones with inadequacy of the respective replacement therapies ( 27 ). IGHD is rare and often treated with GH replacement therapy during childhood. Therefore, the Itabaianinha cohort, with severe congenital and mostly untreated
Department of Psychology II, University of Lübeck, Lübeck, Germany
Search for other papers by Marcus Heldmann in
Google Scholar
PubMed
Search for other papers by Krishna Chatterjee in
Google Scholar
PubMed
Search for other papers by Carla Moran in
Google Scholar
PubMed
Search for other papers by Berenike Rogge in
Google Scholar
PubMed
Search for other papers by Julia Steinhardt in
Google Scholar
PubMed
Search for other papers by Tobias Wagner-Altendorf in
Google Scholar
PubMed
Search for other papers by Martin Göttlich in
Google Scholar
PubMed
Search for other papers by Hannes Schacht in
Google Scholar
PubMed
Search for other papers by Peter Schramm in
Google Scholar
PubMed
Department of Endocrinology, The Christie, University of Manchester, Manchester, UK
Search for other papers by Georg Brabant in
Google Scholar
PubMed
Department of Psychology II, University of Lübeck, Lübeck, Germany
Search for other papers by Thomas F Münte in
Google Scholar
PubMed
Search for other papers by Anna Cirkel in
Google Scholar
PubMed
levothyroxine therapy of primary hypothyroidism . Fertility and Sterility 1983 40 389 – 392 . ( https://doi.org/10.1016/s0015-0282(1647307-3 ) 22 Al Mohareb O AlMalki MH Mueller OT Brema I . Resistance to thyroid hormone-beta co-existing with